Abstract 262P
Background
There are 5,7 male and 3,8 female Non Hodgkin Lymphoma (NHL) patients per 100,000 populations in Indonesia. The expression of pPI3K/pAKT/pMTOR is an important expression in patients with NHL. Cascade signals from these biomarkers lead to translational regulation, cell survival, cytoskeleton organization, and ion transport. Lactate dehydrogenase (LDH) is an important marker in patients with NHL. pPI3K/pAKT/pMTOR increases gene transcription and encourages LDH proliferation.
Methods
An observational study by observing and measuring cancer cell samples from patients. Data collection method is cross sectional in which the independent and dependent variables are examined simultaneously. The expression values of pPI3K, pAKT, and pMTOR are expressed in form of histoscore. There are three range of intensity values which are one means weak, two means medium, and three mean strong, while the four distribution range are one means <20%, two means 20-50%, three means 50-80%, and four means >80%. Therefore the possible range of histoscore is from 1 to 12.
Results
The mean phosphorylated PI3K expression in NHL patients is 5,29 (2,95). The mean phosphorylated AKT expression in NHL patients is 4,71 (2,26). The mean expression of phosphorylated MTOR in NHL patients is 7,62 (1,86). The mean serum LDH level NHL patients is 428,57 (139,63) IU/L.
Conclusions
Correlation between the average expressions of pPI3K with the average level of serum LDH in NHL patients is relatively weak. The correlation between the mean of PAKT expression and the average level of LDH serum in NHL patients is classified as very weak. The correlation between mean pMTOR expression and mean serum LDH levels in NHL patients is very weak.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Andalas University, Padang.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
420TiP - UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
Presenter: Satoru Miura
Session: e-Poster Display Session
443TiP - A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
Presenter: Nathalie Gaspar
Session: e-Poster Display Session
7P - Machine learning intratumoral and axillary lymph node magnetic resonance imaging radiomics for predicting axillary lymph node metastasis in patients with early-stage invasive breast cancer (RBC-01 Study)
Presenter: Yujie Tan
Session: e-Poster Display Session
8P - Knowledge, practice and attitudes of physicians in low- and middle-income countries (LMIC) on fertility and pregnancy-related issues in young breast cancer patients
Presenter: Shah Zeb Khan
Session: e-Poster Display Session
9P - Survival status of elderly women with HR+ early breast cancer: An analysis of SEER database
Presenter: Wang Hao
Session: e-Poster Display Session
10P - Neoadjuvant immunotherapy plus chemotherapy in early triple-negative breast cancer: A meta-analysis of randomized controlled trials
Presenter: Jessa Gilda Pandy
Session: e-Poster Display Session
11P - Genetically predicted bipolar disorder is causally associated with increased risk of breast cancer: A Mendelian randomization analysis
Presenter: Haoxin Peng
Session: e-Poster Display Session
12P - Stromal tumour-infiltrating lymphocytes in human epidermal growth factor receptor 2-overexpressing breast cancer: Association with negative nodal metastasis
Presenter: Ren Xiaoqiu
Session: e-Poster Display Session
13P - A retrospective observational study on neoadjuvant chemotherapy in older adults based on the Joint Breast Cancer Registry Singapore
Presenter: Johan Chan
Session: e-Poster Display Session